Today’s Technologies Used to Develop the Nanomedicines of Tomorrow

12 Mar, 2020 | Newsletters
Today’s Technologies Used to Develop the Nanomedicines of Tomorrow

SPEED UP THE DEVELOPMENT OF NANOMEDICINES

Since the recent outbreak of the Coronavirus or COVID-19, Australian scientists together with colleagues around the world, have been working around the clock to speed up the development of a Coronavirus vaccine.  

LATEST TECHNOLOGIES THAT CAN ACCELERATE YOUR RESEARCH
Our aim is to provide the necessary tools and expertise that will enable researchers to develop such vaccines and other nanomedicines to treat a wide range of diseases and to also aid our understanding of the body’s immune response.

Below is a short list of the latest technologies we support that can speed up the development of novel nanomedicines.  

Contact us more information or visit www.atascientific.com.au

RAPID NANOPARTICLE FORMULATION
NEW NanoAssemblr Ignite uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales. Watch Dr. Justin Richner, explore advances in mRNA Vaccine Therapies in the fields of Cancer Immunotherapy and Infectious Diseases. 
WATCH WEBINAR NOW

NANOPARTICLE & MOLECULAR SIZE
NEW Malvern Zetasizer Ultra. This application note focuses on characterising Adeno-Associated Virus (AAV) using multi-angle dynamic light scattering (MADLS). This technique can be used to determine both the size distribution and concentration of virus samples as well as to provide information on any aggregates present.
DOWNLOAD APPLICATION

LIVE CELL IMAGING & ANALYSIS
Phasefocus Livecyte 2.
Discover how Livecyte can non-invasively detect cell death and can provide both high contrast and quantitative images over a long period to a single cell level, without the need for fluorescent labels. Low illumination power required means cells remain viable post imaging, allowing for additional downstream analysis.
DOWNLOAD APPLICATION

NANOPARTICLE SIZE & CONCENTRATION
NanoSight NS300.  Nanoparticle Tracking Analysis (NTA) can provide a range of useful characterisation information for virus, vaccine and virus-like particle (VLP) applications. Number-based particle concentration can replace plaque assays while subunit vaccines and other protein based therapeutics can be closely monitored for aggregation.
WATCH WEBINAR NOW

LIVE CELL SHIPPER 
CellBox portable CO2 incubator allows both ground and air transport of live cell cultures, tissue and other cell-based samples without the need for freezing, thawing and recovering cells – samples arrive ready to use! 
DOWNLOAD RECENT STUDY

VACCINE FORMULATION STABILITY
MalvernMicroCal PEAQ-DSC. Determine thermal stability of biomolecules to predict shelf-life of biopharmaceuticals, develop purification strategies and rank affinities of ligands to protein targets in small molecule drug discovery.
DOWNLOAD WHITEPAPER

ATA Scientific provides the latest technologies and know-how for you to obtain meaningful and reliable analytical results. To view the current range of instruments we support
Visit www.atascientific.com.au